Weber Capital Management LLC ADV Invests $17.65 Million in AngioDynamics, Inc. $ANGO

Weber Capital Management LLC ADV acquired a new stake in AngioDynamics, Inc. (NASDAQ:ANGO) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 1,356,602 shares of the medical instruments supplier’s stock, valued at approximately $17,649,392. AngioDynamics accounts for about 0.0% of Weber Capital Management LLC ADV’s investment portfolio, making the stock its 4th biggest holding. Weber Capital Management LLC ADV owned about 3.28% of AngioDynamics as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. BlackRock Inc. bought a new position in AngioDynamics in the second quarter worth approximately $49,480,000. Kotler Kevin bought a new stake in shares of AngioDynamics in the fourth quarter worth $21,997,000. UBS Group AG boosted its position in shares of AngioDynamics by 83.6% during the third quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock worth $12,315,000 after acquiring an additional 501,881 shares during the last quarter. Millennium Management LLC boosted its position in shares of AngioDynamics by 28.1% during the third quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after buying an additional 393,682 shares during the period. Finally, Western Standard LLC purchased a new stake in shares of AngioDynamics during the second quarter valued at about $5,037,000. Institutional investors own 89.43% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Canaccord Genuity Group boosted their price objective on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Wall Street Zen raised AngioDynamics from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. HC Wainwright boosted their price objective on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Zacks Research downgraded shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $19.50.

AngioDynamics Price Performance

AngioDynamics stock traded up $0.04 during mid-day trading on Friday, reaching $15.82. 71,870 shares of the company traded hands, compared to its average volume of 472,066. AngioDynamics, Inc. has a fifty-two week low of $9.39 and a fifty-two week high of $16.29. The firm’s fifty day moving average is $14.26 and its two-hundred day moving average is $12.22. The company has a market capitalization of $653.87 million, a price-to-earnings ratio of -18.18 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The company had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, equities research analysts predict that AngioDynamics, Inc. will post -0.25 earnings per share for the current year.

Insider Activity at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the sale, the senior vice president directly owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. This represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.00% of the stock is currently owned by corporate insiders.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.